Search
Tools content (print, share, increase/decrease text size):
-
Size
Middle area:Key facts & figuresSanofi is a diversified global healthcare company engaged in the research, development, manufacture and marketing of healthcare products. Our business includes pharmaceuticals (prescription drugs, consumer healthcare and generics), vaccines and animal health.
|
| € million | 2012 net sales | Change at CER |
|---|---|---|
| Emerging Markets* | 11,145 | +8.3% |
| Emerging Markets
excluding Diabetes, Vaccines, CHC, Animal Health, New Genzyme and Other Innovative Products | 6,286 | +0.5% |
| Diabetes | 5,782 | +16.7% |
| Vaccines | 3,897 | +5.7% |
| Consumer Health Care | 3,008 | +9.9% |
| Animal Health | 2,179 | +3.1% |
| New Genzyme | 1,785 | +16.9%** |
| Other Innovative Products*** | 611 | +10.5% |
| Total Growth Platforms | 23,548 | +9.9% |
| Total Growth Platforms with Genzyme pro forma | 23,548 | +7.8% |
* Include Diabetes, Vaccines, Consumer Health Care, Animal Health, New Genzyme and Other Innovative Products sales generated in Emerging Market.
** On a constant structure basis and at constant exchange rates.
*** Includes recent product launches which do not belong to the other Growth Platforms listed above: Multaq®, Jevtana®, Zaltrap®, and Mozobil® pro forma.
Pharmaceuticals
- 2012 net sales of the pharmaceuticals business: €28,871 million, -0.4% at CER
Sanofi's pharmaceuticals business notably focuses on diabetes, rare diseases, oncology, and other flagship products in anti-thrombotics, cardiovascular, renal and biosurgery fields.
It also includes Consumer Health Care, one of our important growth platforms.
- 2012 net sales of Consumer Health Care: €3,008 million, +9.9% at CER
In addition, our pharmaceuticals portfolio comprises Generics.
- 2012 net sales of Generics: €1,844 million, +5.0% at CER
Human Vaccines
Sanofi Pasteur, the fully integrated Vaccines business of Sanofi, is a world leader in the vaccines industry offering a large range of vaccines covering 20 serious infectious diseases.
- 2012 net sales of the Vaccines business: €3,897 million, + 5.7% at CER
- Non-consolidated 2012 sales of Sanofi Pasteur MSD (50/50 joint-venture with Merck): €845 million, +6.8% on a reported basis
Animal Health
Our Animal Health activity is carried out through Merial, that is one of the world’s leading animal healthcare companies dedicated to the research, development, manufacture and delivery of innovative pharmaceuticals and vaccines used by veterinarians, farmers and pet owners.
- 2012 sales of Merial: €2,179 million, +3.1% at CER
Geographic Presence
Sanofi has a commercial presence in approximately 100 countries, and our products are available in more than 170 countries.
Sanofi is the established leader in Emerging Markets, holding top positions in the main countries. In 2012, Emerging Markets totaled €11,145 million, an increase of 8.3%. Emerging Markets sales contribute to 31.9% of Group sales and are the most important contributors to the region sales.
Right area:
Stock Market
-
May 22, 2013 - 05.37 PM
EURONEXT Paris (SAN) €86.43 +1.52% -
May 22, 2013 - 03.59 PM
NYSE (SNY) $55.06 +0.02%
IAS19R
Amended Accounting Standard on Employee Benefits (IAS19R) applicable as from January 1st, 2013
- Impact of IAS19R
- Comparative segment results for full year 2011
- Comparative segment results for full year 2012
Income Statements
Merial
Historical Consolidated Net Sales
- Sales by geographic region for Genzyme key products in 2011
- Historical consolidated Net Sales by geographic region
- Historical consolidated Pharma Sales by geographic region and product
- Historical consolidated Vaccines Sales by geographic region
Business Net Income
- Adoption of Business Net Income as of Q1 2010
- Business Net Income & Reconciliation of Business Net Income to Adjusted Net Income excluding selected items 2009-2008-2007
Your services
Further information
Event
Publications
SEC Filings
Tools menu:
© Sanofi 2004-2013 - All rights reserved - Update: March 25, 2013
